Vasodilator therapy for primary pulmonary hypertension.
Palevsky
H I
HI
Fishman
A P
AP
D000109:Acetylcholine / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy*; D005996:Nitroglycerin / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D002121:Calcium Channel Blockers; D011453:Prostaglandins; D012702:Serotonin Antagonists; D014665:Vasodilator Agents; D009599:Nitroprusside; D006830:Hydralazine; D005996:Nitroglycerin; D000109:Acetylcholine